Iconiq Capital’s Boston Scientific BSX Stock Holding History

Iconiq Capital’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,166	Closed	-$1.09M	–	142
2025 Q2	$1.09M	Buy	10,166 +818	+9%	+$82.8K	0.02%	96
2025 Q1	$943K	Buy	9,348 +1,922	+26%	+$194K	0.02%	98
2024 Q4	$663K	Buy	7,426 +3,436	+86%	+$302K	0.01%	114
2024 Q3	$334K	Buy	+3,990	New	+$315K	0.01%	132

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Iconiq Capital's BSX Position: Q3 2025 in Review

Iconiq Capital sold out of Boston Scientific (BSX) in Q3 2025, closing a stake of 10,166 shares — an estimated $1.09M sold.

Iconiq Capital first reported a position in BSX in Q3 2024 and held it in 4 quarters. The position peaked at $1.09M in Q2 2025. 1,708 funds tracked by Wall St. Rank hold BSX as of Q3 2025.

Iconiq Capital reported no remaining Boston Scientific position as of Q3 2025 after selling out during the quarter.
Iconiq Capital sold 10,166 Boston Scientific shares in Q3 2025, an estimated $1.09M.
Iconiq Capital first reported a position in Boston Scientific in Q3 2024 and held it in 4 quarters.
Iconiq Capital's Boston Scientific position peaked at $1.09M in Q2 2025.
1,708 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2025.

Based on Iconiq Capital's 13F filing for Q3 2025, filed 14 Nov 2025.